NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

NGM Biopharmaceuticals, Inc. (NGM), a biotechnology firm, announced CEO David J. Woodhouse will join the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 am ET. He will discuss NGM's wholly-owned oncology portfolio as part of the Novel Oncology Targets Panel.

A live webcast will be available on NGM’s website, with a replay accessible for 30 days post-event. NGM focuses on developing transformative therapies, with a portfolio that includes four solid tumor oncology programs currently in clinical development.

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43^rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tuesday, March 7^th, at 9:10 am ET.

A live webcast of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM Bio’s site for at least 30 days following the event.

About NGM Biopharmaceuticals, Inc.

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Today, the company has four solid tumor oncology programs in clinical development. Visit us at www.ngmbio.com for more information.

Investor Contact:	Media Contact:
Brian Schoelkopf	media@ngmbio.com
ir@ngmbio.com

FAQ

When will NGM Biopharmaceuticals participate in the Cowen 43rd Annual Health Care Conference?

NGM will participate in the conference on March 7, 2023, at 9:10 am ET.

What will be discussed by NGM's CEO at the Cowen Health Care Conference?

David J. Woodhouse will provide a business update on NGM's wholly-owned oncology portfolio.

Where can I watch the presentation by NGM Biopharmaceuticals?

The presentation will be available via a live webcast on NGM's Investors and Media section of their website.

How long will the NGM Biopharmaceuticals presentation replay be available?

The replay of the presentation will be available for at least 30 days after the event.

What is the focus of NGM Biopharmaceuticals in drug development?

NGM focuses on discovering and developing novel therapies for patients with unmet medical needs, particularly in oncology.

How many oncology programs does NGM Biopharmaceuticals have in clinical development?

NGM has four solid tumor oncology programs currently in clinical development.